Bolt Metals Corp
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 100
- Market Cap
- -
- Website
- http://www.boltbio.com
- Introduction
Bolt Metals Corp is engaged in the acquisition and exploration of mineral exploration and evaluation assets in Indonesia. The company owns a nickel project named Cyclops located in Indonesia. It operates in a single reportable operating segment the Acquisition and exploration of exploration and evaluation assets located in Indonesia and Canada.
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
- Conditions
- Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT06921837
- Locations
- 🇦🇺
AUS Site 2, Darlinghurst, New South Wales, Australia
🇦🇺AUS Site 1, Birtinya, Queensland, Australia
Study of BDC-3042 As Single Agent and in Combination with Cemiplimab in Patients with Advanced Malignancies
- Conditions
- Triple Negative Breast CancerColorectal CancerClear Cell Renal Cell CarcinomaMelanomaHead and Neck CancerOvarian CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT06052852
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Trial of BDC-1001 +/- Pertuzumab in Subjects with HER2-Positive Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05954143
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Virginia Cancer Specialists, Arlington, Virginia, United States
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
A First-in-human Study Using BDC-1001 As a Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors
- Conditions
- HER2-positive Colorectal CancerHER2-positive Solid TumorsHER2-positive Endometrial CancerHER2-positive Breast CancerHER2-positive Gastroesophageal Cancer
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT04278144
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States